Minerva up on seeking FDA approval for schizophrenia treatment

Minerva Neurosciences

22/08/2022 14:15

** Shares of drug developer Minerva Neurosciences  NERV.O 
up 5.6% at $3.28 before the bell
    ** Co submits marketing application with U.S. FDA for
approval of its experimental therapy, roluperidone, to treat
negative symptoms in patients with schizophrenia  urn:newsml:reuters.com:*:nGNX3tz9Hh
    ** Schizophrenia is a chronic, severe mental disorder;
psychotic symptoms include hallucinations and unusual thinking
while negative symptoms include disinterest in daily activities
and social withdrawal
    ** Up to Friday's close, stock was down ~52% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))